EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 18 / No 6-7 (Juin–Juillet 2002) Med Sci (Paris), 18 6-7 (2002) 689-696 References
Free Access
Issue
Med Sci (Paris)
Volume 18, Number 6-7, Juin–Juillet 2002
Page(s) 689 - 696
Section M/S Revues : Articles de Synthèse
DOI https://doi.org/10.1051/medsci/20021867689
Published online 15 June 2002
  1. Lebert F, Pasquier F. Signes et symptômes comportementaux et psychologiques de la démence. Encycl Méd Chir (Elsevier Paris) Neurologie 1999, 17-057, A35, 7 p. [Google Scholar]
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington DC : APA, 1995. [Google Scholar]
  3. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease : report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer disease. Neurology 1984; 34 : 939–44. [Google Scholar]
  4. Geldmacher DS, Whitehouse PJ. Differential diagnosis of Alzheimer’s disease. Neurology 1997; 48 (suppl 5) : S2–9. [Google Scholar]
  5. De Rotrou J, Forette F, Hervy MP, et al. The cognitive efficiency profile : description and validation in patients with Alzheimer disease.Int J Geriatr Psychiatr 1991; 6 : 501–9. [Google Scholar]
  6. DeJong R, Osterlund OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11 : 545–54. [Google Scholar]
  7. Reisberg B, Ferris SH, de Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139 : 1136–9. [Google Scholar]
  8. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12 : 189–98. [Google Scholar]
  9. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44 : 2308–14. [Google Scholar]
  10. Zarit, SH, Orr NK, Zarit J.M. The hidden victims of Alzheimer’s disease: families under stress. New York : New York University Press, 1985. [Google Scholar]
  11. Knopman DS, Knapp MJ, Gracon SI, et al. The clinician interview based impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology 1994; 44 : 2315–21. [Google Scholar]
  12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141 : 1356–64. [Google Scholar]
  13. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of duration of survival after the onset of dementia. N Engl J Med 2001; 344 : 1111–6. [Google Scholar]
  14. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease, JAMA 1994; 271 : 985–91. [Google Scholar]
  15. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease. Results from a multinational trial. Dement Geriatr Cogn Disord 1999; 52 : 1138–45. [Google Scholar]
  16. Rossler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease : international randomised controlled trial. Br Med J 1999; 318 : 633–8. [Google Scholar]
  17. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD : a 6-month randomized, plaebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54 : 2261–8. [Google Scholar]
  18. Sano M, Ernesto C, Thomas R, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. the Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336 : 1216–22. [Google Scholar]
  19. Aisen PA. Inflammation and Alzheimer’s disease: mechanisms and therapeutic strategies. Gerontology 1997; 43 : 143–9. [Google Scholar]
  20. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43 : 1609–11. [Google Scholar]
  21. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 2000; 54 : 588–93. [Google Scholar]
  22. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease. Neurology 1997; 48 : 1517–21. [Google Scholar]
  23. Women’s Health Initiative Study Group. Design of the women’s health initiative clinical trial and observational study. Control Clin Trials 1998; 19 : 61–109. [Google Scholar]
  24. Henderson VW, Paganini Hill A, Miller BL, et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebocontrolled trial. Neurology 2000; 54 : 295–301. [Google Scholar]
  25. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 2000; 283 : 1007–15. [Google Scholar]
  26. Ott A, Stolk RP, Hofman A, van Harskamp F, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996; 39 : 1392–7. [Google Scholar]
  27. Merchant C, Tang MX, Albert S, et al. The influence of smoking on the risk of Alzheimer’s disease. Neurology 1999; 52 : 1408–12. [Google Scholar]
  28. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000;356 : 1627–31. [Google Scholar]
  29. Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57 : 1439–43. [Google Scholar]
  30. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta - amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98 : 5856–61. [Google Scholar]
  31. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352 : 1347–51. [Google Scholar]
  32. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265 : 3255–64. [Google Scholar]
  33. Kokmen E, Whisnant JP, O’Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke. A population based study in Rochester, Minnesota (1960-1984). Neurology 1996; 46 : 154–9. [Google Scholar]
  34. Progress Collaborative Group. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358 : 1033–41. [Google Scholar]
  35. Tollefson GD. Short term effect of the calcium blocker nimodipine in the management of primary degenerative dementia. Biol Psychiatry 1990; 27 : 1133–42. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.